NO20063931L - Nye sammensetninger inneholdende kinolinforbindelser - Google Patents

Nye sammensetninger inneholdende kinolinforbindelser

Info

Publication number
NO20063931L
NO20063931L NO20063931A NO20063931A NO20063931L NO 20063931 L NO20063931 L NO 20063931L NO 20063931 A NO20063931 A NO 20063931A NO 20063931 A NO20063931 A NO 20063931A NO 20063931 L NO20063931 L NO 20063931L
Authority
NO
Norway
Prior art keywords
salt
formula
compositions containing
new compositions
quinoline compounds
Prior art date
Application number
NO20063931A
Other languages
English (en)
Other versions
NO337235B1 (no
Inventor
Anders Bjork
Karl Jansson
Tomas Fristedt
Hans Wannman
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of NO20063931L publication Critical patent/NO20063931L/no
Publication of NO337235B1 publication Critical patent/NO337235B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En stabil fast farmasøytisk sammensetning bestående hovedsakelig av en effektiv mengde av et salt med formel (II) sammen med en alkalireagerende komponent som opprettholder pHen fortrinnsvis over 8, eller et salt med et divalent metallkation; og minst en farmasøytisk eksipient; saltet med formel (II) er hovedsakelig stabilt under lagring ved romtemperatur i en periode på minst 3 år.En fremgangsmåte for a stabilisere saltet med. formel (II).Et krystallinsk salt med formel (II) og en fremgangsmåte for a fremstille saltet.
NO20063931A 2004-02-06 2006-09-04 Nye sammensetninger inneholdende kinolinforbindelser NO337235B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400235A SE0400235D0 (sv) 2004-02-06 2004-02-06 New composition containing quinoline compounds
PCT/EP2005/050485 WO2005074899A2 (en) 2004-02-06 2005-02-04 New compositions containing quinoline compounds

Publications (2)

Publication Number Publication Date
NO20063931L true NO20063931L (no) 2006-09-04
NO337235B1 NO337235B1 (no) 2016-02-15

Family

ID=31885235

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063931A NO337235B1 (no) 2004-02-06 2006-09-04 Nye sammensetninger inneholdende kinolinforbindelser

Country Status (26)

Country Link
US (1) US7589208B2 (no)
EP (1) EP1720531B1 (no)
JP (1) JP4864724B2 (no)
KR (3) KR101189557B1 (no)
CN (1) CN1980669B (no)
AP (1) AP2395A (no)
AT (1) ATE505186T1 (no)
AU (1) AU2005210174B2 (no)
BR (1) BRPI0506906B1 (no)
CA (1) CA2552463C (no)
CY (1) CY1111697T1 (no)
DE (1) DE602005027445D1 (no)
DK (1) DK1720531T3 (no)
ES (1) ES2364754T3 (no)
HK (1) HK1105866A1 (no)
IL (1) IL176255A (no)
NO (1) NO337235B1 (no)
NZ (1) NZ548469A (no)
PL (1) PL1720531T3 (no)
PT (1) PT1720531E (no)
RU (1) RU2339622C2 (no)
SE (1) SE0400235D0 (no)
SI (1) SI1720531T1 (no)
UA (1) UA90463C2 (no)
WO (1) WO2005074899A2 (no)
ZA (1) ZA200605619B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
WO2005067887A2 (en) * 2004-03-24 2005-07-28 Actavis Group Formulations of ramipril
BR122018075478B8 (pt) 2004-06-24 2023-10-31 Vertex Pharma moduladores de transportadores de cassete de ligação de atp
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
WO2007047863A2 (en) 2005-10-19 2007-04-26 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
AU2016219571B2 (en) * 2005-12-28 2018-03-15 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
HUE049976T2 (hu) 2005-12-28 2020-11-30 Vertex Pharma N-[2,4-bisz(1,1-dimetil-etil)-5-hidroxi-fenil]-1,4-dihidro-4-oxo-kinolin-3-karboxamid amorf alakjának gyógyászati kompozíciói
AU2013201426B2 (en) * 2005-12-28 2016-06-02 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR101495327B1 (ko) * 2006-06-12 2015-02-24 테바 파마슈티컬 인더스트리즈 리미티드 안정한 라퀴니모드 제제
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
JPWO2009069280A1 (ja) * 2007-11-27 2011-04-07 大原薬品工業株式会社 造粒物の製造法
WO2009082471A1 (en) * 2007-12-20 2009-07-02 Teva Pharmaceutical Industries, Ltd. Stable laquinimod preparations
EP2318371A2 (en) * 2008-07-01 2011-05-11 Actavis Group PTC EHF Novel solid state forms of laquinimod and its sodium salt
CA2736091A1 (en) 2008-09-03 2010-03-11 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
NZ623273A (en) * 2008-12-05 2015-09-25 Abraxis Bioscience Llc Sparc binding scfvs
DE102008064379A1 (de) * 2008-12-22 2010-07-15 Siemens Aktiengesellschaft Magnetspulenanordnung mit festen und beweglichen Spulen
SG10201504084QA (en) 2009-03-20 2015-06-29 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
JP5503192B2 (ja) * 2009-06-03 2014-05-28 大原薬品工業株式会社 生理活性物質含有粒子の製造方法
AU2010260455A1 (en) * 2009-06-19 2012-02-02 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
SI2458992T1 (sl) * 2009-07-30 2016-03-31 Teva Pharmaceutical Industries Ltd. Zdravljenje Crohnove bolezni z lakvinimodom
JP5859438B2 (ja) 2009-08-10 2016-02-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを用いたｂｄｎｆ関連疾患の治療
US20130035390A1 (en) 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
JP2013516459A (ja) * 2010-01-20 2013-05-13 カディラ・ヘルスケア・リミテッド ピタバスタチン及び医薬として許容可能なそれらの塩の製造方法
BR112012022064A2 (pt) * 2010-03-03 2015-09-08 Teva Pharma tratamento de artrite lúpica usando laquinimod
ES2558556T3 (es) 2010-03-03 2016-02-05 Teva Pharmaceutical Industries Ltd. Tratamiento de nefritis lúpica usando laquinimod
BR112012022187A2 (pt) 2010-03-03 2015-09-22 Teva Pharma tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato
WO2011117225A1 (de) 2010-03-23 2011-09-29 Vifor (International) Ag Fe(iii)-komplexverbindungen zur behandlung und prophylaxe von eisenmangelerscheinungen und eisenmangelanämien
SG186948A1 (en) * 2010-07-09 2013-02-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
KR20130041193A (ko) 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
RU2013120556A (ru) 2010-10-14 2014-11-20 Иммунар Аб 1,2-гидрокси-2-оксо-хинолин-3-карбоксанилиды в качестве активаторов ahr
AR086606A1 (es) 2011-05-31 2014-01-08 Vifor Int Ag Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
EP2766020A4 (en) 2011-10-12 2015-04-01 Teva Pharma TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
JP6215238B2 (ja) * 2012-02-16 2017-10-18 テバ ファーマシューティカル インダストリーズ リミティド Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
CN109966264A (zh) 2012-02-27 2019-07-05 沃泰克斯药物股份有限公司 药物组合物及其施用
US20130259856A1 (en) 2012-03-27 2013-10-03 Teva Pharmaceutical Industries, Ltd. Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AR091706A1 (es) * 2012-07-11 2015-02-25 Teva Pharma Formulaciones de laquinimod sin agentes alcalinizantes
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
MX2015005632A (es) 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
CN105246473B (zh) 2012-12-21 2018-07-13 维福（国际）股份有限公司 用于缺铁症状和缺铁性贫血的治疗和预防的Fe(III)络合化合物
BR112015021602A2 (pt) 2013-03-14 2017-07-18 Teva Pharma cristais de laquinimod de sódio e processo melhorado para a fabricação dos mesmos
MX2015010967A (es) 2013-03-14 2015-10-26 Teva Pharma Formulaciones transdermicas de laquinimod.
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
KR102533033B1 (ko) 2014-09-23 2023-05-15 액티브 바이오테크 에이비 다발성 골수종의 치료에 사용하기 위한 퀴놀린 카르복사미드
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
AU2015348778B2 (en) 2014-11-19 2020-12-24 Active Biotech Ab Quinoline carboxamides for use in the treatment of leukemia
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
KR20180065223A (ko) 2016-12-07 2018-06-18 순천향대학교 산학협력단 천식의 치료 또는 완화용 약학 조성물
CN112703036A (zh) 2018-08-15 2021-04-23 法玛西尔有限公司 取代的苯甲酰胺及其在疗法中的用途
CA3108361A1 (en) 2018-08-15 2020-02-20 Pharmacyl Ab A new medical treatment for pathologic inflammation
AU2021275994A1 (en) * 2020-05-21 2022-12-22 Stemsynergy Therapeutics, Inc. Notch inhibitors and uses thereof
AU2021313388A1 (en) 2020-07-23 2023-01-19 Erasmus University Medical Center Rotterdam (Erasmus Mc) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340735A1 (fr) 1976-02-11 1977-09-09 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5077851A (en) * 1989-02-27 1992-01-07 Guma Juan M Method and apparatus for treating corded fabrics
SE8902076D0 (sv) 1989-06-09 1989-06-09 Pharmacia Ab Derivatives of quinoline-3-carboxanilide
HUT60458A (en) 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
DE122011000014I1 (de) 1995-12-22 2011-11-03 Kowa Co Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
WO1997041108A1 (en) * 1996-04-30 1997-11-06 Warner-Lambert Company Substituted piperazines and piperidines as central nervous system agents
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6133285A (en) 1998-07-15 2000-10-17 Active Biotech Ab Quinoline derivatives
US6121287A (en) 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
RS51019B (sr) * 1999-10-25 2010-10-31 Active Biotech Ab. Lekovi za lečenje malignih tumora
SE0002320D0 (sv) * 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives

Also Published As

Publication number Publication date
IL176255A (en) 2011-11-30
HK1105866A1 (en) 2008-02-29
DE602005027445D1 (de) 2011-05-26
ES2364754T3 (es) 2011-09-13
ZA200605619B (en) 2007-11-28
PT1720531E (pt) 2011-06-27
CA2552463A1 (en) 2005-08-18
KR20130012084A (ko) 2013-01-31
RU2006132070A (ru) 2008-03-20
RU2339622C2 (ru) 2008-11-27
US7589208B2 (en) 2009-09-15
CN1980669A (zh) 2007-06-13
BRPI0506906B1 (pt) 2018-05-15
US20050192315A1 (en) 2005-09-01
CA2552463C (en) 2013-05-14
CY1111697T1 (el) 2015-10-07
EP1720531B1 (en) 2011-04-13
DK1720531T3 (da) 2011-08-01
ATE505186T1 (de) 2011-04-15
BRPI0506906A (pt) 2007-05-29
WO2005074899A3 (en) 2007-04-19
WO2005074899A2 (en) 2005-08-18
CN1980669B (zh) 2011-11-30
IL176255A0 (en) 2006-10-05
SI1720531T1 (sl) 2011-08-31
AU2005210174A1 (en) 2005-08-18
KR101189557B1 (ko) 2012-10-12
AP2395A (en) 2012-04-10
KR20060130191A (ko) 2006-12-18
JP4864724B2 (ja) 2012-02-01
AP2006003674A0 (en) 2006-08-31
PL1720531T3 (pl) 2011-09-30
AU2005210174B2 (en) 2010-10-07
KR101457463B1 (ko) 2014-11-04
EP1720531A2 (en) 2006-11-15
UA90463C2 (ru) 2010-05-11
NO337235B1 (no) 2016-02-15
KR20120062029A (ko) 2012-06-13
SE0400235D0 (sv) 2004-02-06
NZ548469A (en) 2010-05-28
JP2007520529A (ja) 2007-07-26

Similar Documents

Publication Publication Date Title
NO20063931L (no) Nye sammensetninger inneholdende kinolinforbindelser
MD4157B1 (en) Isoxazolines for controlling invertebrate pests
WO2007070606A3 (en) Isoxazolines for controlling invertebrate pests
WO2003057688A3 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
CA2555258A1 (en) 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
NO983493L (no) Nye benzimidazol-, benzoksazol- og benzotiazolforbindelser, fremgangsmÕte ved fremstilling derav og farmas°ytiske sammensetninger inneholdende slike
CA2495577A1 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
NO20004281L (no) 6,9-disubstituerte 2-[trans-(4-aminocykloheksyl)amino]puriner, farmasoytisk preparat inneholdende disse, og anvendelse derav for fremstilling av et medikament
FI893751A (fi) Kemiska foereningar.
WO2010012762A3 (de) Farbstabiler superabsorber
PT2113502E (pt) Compostos do tipo hidrazida e sua utilização em composições farmacêuticas para o tratamento das doenças cardiovasculares
WO2004031160A3 (fr) Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
NO20060718L (no) Substituerte tiofoner og deres anvendelse
NO20074504L (no) Farmasoytisk aktive forbindelser, deres fremstilling, sammensetninger inneholdende dem og deres anvendelse
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
GEP20074256B (en) Novel benzothiadiazine, process for their preparation and pharmaceutical compositions containing
DK0458551T3 (da) Spiro-isoquinolin-pyrrolidiner og analoge deraf, som er anvendelige som aldosereduktase-inhibitorer.
WO2003072576A3 (en) Oxazolidinone derivatives, processes for their preparation, and pharmaceutical compositions containing them
EP3609494A1 (en) Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelate pathway
GR3033519T3 (en) Substituted pyridinesulfonamide compounds, herbicidal compositions containing them, and process for their production.
NO905086D0 (no) Immunostimulerende 6-aryl-5,6-dihydroimidazo(2,1-b)tiazolderivater og fremgangsmaate for deres fremstilling.
AU2122592A (en) Heterocyclic sulfonylglycine derivatives
HUT58187A (en) Herbicide compositions containing dicarboxylic-imides as active components and process for producing the active components

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees